Mikaela Naylon Give Kids a Chance Act

Key Points

• Drug companies will be required to study how new cancer treatments work for children, especially when used in combination with existing medicines. This aims to find better treatments for childhood cancers that are often overlooked by researchers focusing on adults.
• The bill extends a program until 2029 that rewards companies for developing drugs for rare childhood diseases. These rewards, known as vouchers, allow companies to get a future drug reviewed faster by the government, which encourages them to invest in medicines for small groups of sick children.
• It changes rules for 'orphan drugs' to prevent companies from having a total monopoly on a rare disease. Special protections will now only apply to the specific use of the drug that was approved, rather than the entire disease, making it easier for other companies to develop different treatments.
• The national organ transplant system will get a technology upgrade to help more patients. This includes better electronic record sharing between hospitals and a new public dashboard to track how many transplants are happening and how many organs are unfortunately going unused.
• Generic drug makers will get more help from the government to make sure their products match brand-name drugs exactly. By providing more transparency about ingredients, the government hopes to help cheaper generic medicines reach the market faster.
• The bill increases funding for a Medicare improvement fund by over $1.2 billion and creates a new international office to help partner countries in the Middle East meet safety standards for medical products.

Votes

No votes have been recorded for this legislation yet.